How do you decide between systemic vs. arterially directed therapies in the first line setting for unresectable HCC?  

In IMbrave150, 63% of patients treated with atezolizumab/bevacizumab had extrahepatic spread of disease, and my recommendation for patients with extrahepatic involvement is for first line systemic therapy. For patients with unresectable disease without extrahepatic spread, we take a multi-disciplin...

Unresectable HCC represents a broad group of HCC patients. For patients with liver limited disease without vascular invasion, I rely on tumor burden to determine whether to start with liver directed therapy versus systemic therapy. IN general, patients with multifocal bilobar or multilobar disease, ...